Quick Answer
SUPERNUS PHARMACEUTICALS, INC. reported Total Revenue of $718.95 million for fiscal year 2025.
SUPERNUS PHARMACEUTICALS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $718.95M +8.6% |
$661.82M +8.9% |
$607.52M -8.9% |
$667.24M +15.1% |
$579.77M +11.4% |
$520.40M +32.5% |
| Revenue (ASC 606) | $718.95M +8.6% |
$661.82M +8.9% |
$607.52M -8.9% |
$667.24M +15.1% |
$579.77M +11.4% |
$520.40M +32.5% |
| Net Income | -$38.55M -152.2% |
$73.86M +5512.8% |
$1.32M -97.8% |
$60.71M +13.6% |
$53.42M -57.9% |
$126.95M +12.3% |
| Diluted EPS | -$0.68 -151.5% |
$1.32 +6500.0% |
$0.02 -98.1% |
$1.04 +6.1% |
$0.98 -58.5% |
$2.36 +12.4% |
| Total Assets | $1.45B +6.2% |
$1.37B +7.1% |
$1.28B -25.0% |
$1.70B +0.8% |
$1.69B +12.3% |
$1.50B +29.6% |
| Cash and Equivalents | $128.45M +85.3% |
$69.33M -7.6% |
$75.05M -19.4% |
$93.12M -54.2% |
$203.43M -29.5% |
$288.64M +59.1% |
| Stockholders Equity | $1.06B +2.5% |
$1.04B +12.4% |
$921.52M +4.0% |
$886.20M +8.6% |
$815.85M +9.5% |
$744.86M +25.1% |
| R&D Expense | $106.23M -2.4% |
$108.80M +18.8% |
$91.59M +22.9% |
$74.55M -17.6% |
$90.47M +19.1% |
$75.96M +9.9% |
| Operating Income | -$62.28M -176.3% |
$81.67M +1649.9% |
-$5.27M -111.4% |
$46.12M -46.4% |
$86.03M -50.5% |
$173.70M +16.9% |
| Shares Outstanding | 57.46M +3.1% |
55.74M +1.9% |
54.72M +0.9% |
54.25M +1.9% |
53.26M +0.7% |
52.87M +0.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $192.10M | +9.3% | +16.1% |
| Revenue (ASC 606) | September 30, 2025 | $192.10M | +9.3% | +16.1% |
| Net Income | September 30, 2025 | -$45.12M | -217.2% | -300.5% |
| Diluted EPS | September 30, 2025 | -$0.80 | -215.9% | -300.0% |
| Total Assets | September 30, 2025 | $1.42B | +5.7% | +2.7% |
| Cash and Equivalents | September 30, 2025 | $151.37M | +377.9% | +4.6% |
| Long-Term Debt | September 30, 2022 | $0.00 | — | — |
| Stockholders Equity | September 30, 2025 | $1.05B | +4.2% | -1.3% |
| R&D Expense | September 30, 2025 | $29.37M | +1.1% | +32.8% |
| Operating Income | September 30, 2025 | -$60.23M | -247.5% | -596.1% |
| Shares Outstanding | September 30, 2025 | 57.12M | +3.4% | +1.8% |
- SUPERNUS PHARMACEUTICALS, INC. reported Total Revenue of $718.95 million for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +8.6% in Total Revenue compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $718.95 million for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +8.6% in Revenue (ASC 606) compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Net Income of -$38.55 million for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -152.2% in Net Income compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Diluted EPS of $0.68 per share (loss) for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -151.5% in Diluted EPS compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Total Assets of $1.45 billion for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +6.2% in Total Assets compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Cash and Equivalents of $128.45 million for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +85.3% in Cash and Equivalents compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Stockholders Equity of $1.06 billion for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +2.5% in Stockholders Equity compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported R&D Expense of $106.23 million for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -2.4% in R&D Expense compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Operating Income of -$62.28 million for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed a decrease of -176.3% in Operating Income compared to the prior fiscal year.
- SUPERNUS PHARMACEUTICALS, INC. reported Shares Outstanding of 57.46 million shares for fiscal year 2025.
- SUPERNUS PHARMACEUTICALS, INC. showed an increase of +3.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: